Insmed (NASDAQ:INSM) Hits New 52-Week High – Here’s What Happened

Shares of Insmed, Inc. (NASDAQ:INSM) reached a new 52-week high during trading on Monday . The company traded as high as $169.99 and last traded at $165.77, with a volume of 1383 shares. The stock had previously closed at $165.76.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. JPMorgan Chase & Co. increased their price objective on shares of Insmed from $111.00 to $135.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 20th. Stifel Nicolaus upped their target price on Insmed from $121.00 to $145.00 and gave the company a “buy” rating in a research note on Thursday, August 14th. Jefferies Financial Group raised their price target on Insmed from $129.00 to $148.00 and gave the stock a “buy” rating in a research note on Wednesday, August 13th. Wells Fargo & Company began coverage on Insmed in a report on Monday. They set an “overweight” rating and a $171.00 price objective for the company. Finally, Guggenheim upped their price objective on Insmed from $125.00 to $172.00 and gave the company a “buy” rating in a research report on Monday, September 8th. Nineteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $152.88.

Insmed Stock Performance

The firm has a 50 day moving average of $145.35 and a 200-day moving average of $106.37. The company has a market cap of $34.94 billion, a P/E ratio of -28.95 and a beta of 1.03. The company has a quick ratio of 6.33, a current ratio of 6.68 and a debt-to-equity ratio of 0.45.

Insmed (NASDAQ:INSM) last issued its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.30) by ($0.40). Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. The firm had revenue of $107.42 million for the quarter, compared to the consensus estimate of $104.06 million. During the same period last year, the firm earned ($1.94) earnings per share. The company’s revenue for the quarter was up 18.9% on a year-over-year basis. Insmed has set its FY 2025 guidance at EPS. As a group, sell-side analysts anticipate that Insmed, Inc. will post -4.56 EPS for the current fiscal year.

Insider Activity at Insmed

In other Insmed news, Director Melvin Md Sharoky sold 10,000 shares of the firm’s stock in a transaction dated Friday, September 12th. The shares were sold at an average price of $145.39, for a total transaction of $1,453,900.00. Following the transaction, the director owned 262,675 shares of the company’s stock, valued at approximately $38,190,318.25. This trade represents a 3.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Roger Adsett sold 25,000 shares of the business’s stock in a transaction dated Tuesday, August 19th. The shares were sold at an average price of $127.58, for a total transaction of $3,189,500.00. Following the completion of the sale, the chief operating officer owned 105,637 shares of the company’s stock, valued at approximately $13,477,168.46. This represents a 19.14% decrease in their position. The disclosure for this sale can be found here. Insiders sold 152,657 shares of company stock worth $21,442,198 over the last quarter. Corporate insiders own 3.00% of the company’s stock.

Institutional Trading of Insmed

Hedge funds have recently bought and sold shares of the stock. Moody Aldrich Partners LLC lifted its position in shares of Insmed by 2.4% in the third quarter. Moody Aldrich Partners LLC now owns 5,551 shares of the biopharmaceutical company’s stock valued at $799,000 after acquiring an additional 132 shares in the last quarter. M&T Bank Corp raised its stake in Insmed by 4.7% in the 1st quarter. M&T Bank Corp now owns 3,293 shares of the biopharmaceutical company’s stock valued at $252,000 after purchasing an additional 147 shares during the last quarter. First Horizon Advisors Inc. lifted its holdings in Insmed by 24.8% in the 2nd quarter. First Horizon Advisors Inc. now owns 936 shares of the biopharmaceutical company’s stock valued at $94,000 after purchasing an additional 186 shares in the last quarter. Yousif Capital Management LLC lifted its holdings in Insmed by 9.3% in the 3rd quarter. Yousif Capital Management LLC now owns 2,188 shares of the biopharmaceutical company’s stock valued at $315,000 after purchasing an additional 187 shares in the last quarter. Finally, ORG Partners LLC boosted its stake in Insmed by 220.2% during the 2nd quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 196 shares during the last quarter.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.